Psychedelic Therapy Scrutinized by FDA Advisory Committee?

The Psychopharmacologic Drugs Advisory Committee's decisions on MDMA-assisted therapy carry significant implications for the future of psychedelic research. The committee's evaluations highlight the complex regulatory and scientific challenges facing this emerging treatment modality. Their rulings may shape how subsequent studies are designed, what endpoints are considered acceptable, and how safety and efficacy data are interpreted. The analysis suggests that these decisions could either accelerate or hinder the development of psychedelic therapies, depending on how the field responds to the committee's concerns about trial methodology, blinding, and potential for abuse.

Study at a glance

Abstract

This Viewpoint analyzes the Psychopharmacologic Drugs Advisory Committee’s decisions regarding 3,4-methylenedioxymethamphetamine–assisted therapy and what they mean for psychedelic research.